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PTreatment of Hypertrophic Cardiomyopathy: Point–Counterpoint
he Case for Surgery
n Obstructive Hypertrophic Cardiomyopathy
arry J. Maron, MD, FACC,* Joseph A. Dearani, MD,†
teve R. Ommen, MD, FACC,† Martin S. Maron, MD,‡ Hartzell V. Schaff, MD, FACC,†
ernard J. Gersh, MB, MBCHB, DPHIL, FACC,† Rick A. Nishimura, MD, FACC†
inneapolis and Rochester, Minnesota; and Boston, Massachusetts
Relief of left ventricular (LV) outflow obstruction in patients with hypertrophic cardiomy-
opathy (HCM) and disabling symptoms refractory to maximum medical management has
historically been a surgical problem. Surgical septal myectomy permanently abolishes systolic
anterior motion of the mitral valve and mitral regurgitation, while normalizing LV pressures
and wall stress. Also, these salutary goals are achieved without encumbering patients with
post-procedural devices (e.g., pacemakers or defibrillators) or creating potentially arrhythmo-
genic substrates, as may occur with alcohol septal ablation. Procedural morbidity and
mortality risk with myectomy is similar to, and in some institutions less than those for alcohol
septal ablation. Over four decades, reports from numerous centers worldwide have consis-
tently and unequivocably documented the benefits of surgery on hemodynamic and functional
state, restoring normal and acceptable quality of life to patients of all ages by largely reversing
the complications of heart failure. Long-term survival after myectomy is similar to that of the
general population and superior to non-operated patients with obstruction. The LV outflow
tract morphology in HCM is heterogeneous and not uncommonly includes congenital
anomalies of the mitral valve apparatus for which the surgeon has the flexibility to adapt the
repair, often employing an extended myectomy. In the current atmosphere of increasing and
perhaps excessive enthusiasm for newer catheter-based interventions, it is a critical time to
promote and re-emphasize that surgery is the time-honored (and presently the most effective)
treatment strategy for relieving heart failure-related disability resulting from dynamic LV
outflow obstruction in HCM, and is the primary treatment option for this subgroup of
severely symptomatic drug-refractory patients. (J Am Coll Cardiol 2004;44:2044–53)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.04.063© 2004 by the American College of Cardiology Foundation
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tISTORICAL CONTEXT
istorically, surgery has been the primary strategy for
elieving left ventricular (LV) outflow obstruction in pa-
ients with hypertrophic cardiomyopathy (HCM) and se-
ere limiting symptoms unresponsive to maximum medical
anagement (1,2). A recently introduced catheter-based
ntervention (alcohol septal ablation) has experienced a
urge in popularity among interventional cardiologists (1).
n the present discussion, we wish to re-emphasize the
ppropriate role and visibility of surgical septal myectomy in
he treatment of obstructive HCM, and in the process
rudently balance the presently skewed ongoing debate
etween percutaneous techniques and cardiac surgery.
Since the first modern reports in the late 1950s (3,4),
CM has been regarded as a genetic heart disease charac-
erized by asymmetric LV hypertrophy and dynamic out-
ow obstruction (1,2,5–18). Indeed, the common nonob-
tructive form of HCM was not fully appreciated until the
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Manuscript received December 18, 2003; revised manuscript received April 21,
004, accepted April 27, 2004.dvent of echocardiography in the early 1970s (1). Despite
eriodic controversy (19–21), substantial clinical importance
as been attributed to LV outflow obstruction through the
ears, with patient management often predicated on the
resence (or absence) of a subaortic gradient (1,2,7–11).
However, only recently was the long-term pathophysio-
ogic significance of obstruction leading to progressive heart
ailure and cardiovascular death substantiated in a large and
rospectively enrolled HCM population (22). It is now
enerally accepted that outflow tract gradients (and associ-
ted mitral regurgitation) represent adverse consequences of
CM, cause mechanical impedance to LV ejection, and are
major cause of disabling symptoms at any age.
Surgical intervention for obstructive HCM was first
erformed by Cleland (23) in the United Kingdom, but the
rocedure was abandoned owing to high operative mortal-
ty. Subsequently, surgical techniques were pioneered in
orth America by Morrow (24) at the National Institutes of
ealth, Kirklin (25) at Mayo Clinic, and Bigelow et al. (26)
t Toronto General Hospital, and then quickly adopted by
ther U.S. and Western European centers. Paradoxically,
arly surgical efforts in the 1960s went forward even though
he mechanism by which obstruction occurs, that is, systolic
nterior motion of the mitral valve with prolonged mid-
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November 16, 2004:2044–53 The Case for HCM Surgeryystolic septal apposition, had not yet been recognized, and
ubaortic gradients were regarded as the consequence of a
phincter-like, muscular outflow tract contraction ring
5,6,24).
HE SURGICAL APPROACH
urgery for obstructive HCM, traditionally performed in
pecialized tertiary centers, has evolved over the past four
ecades, from ventricular septal myotomy (i.e., without
uscular resection) (26), to the classic Morrow myectomy
24). More recently, an extended and more extensive my-
ctomy (up to about 7 cm long compared with 3 cm for the
tandard Morrow resection), combined with repair of mitral
alve and submitral abnormalities, is practiced by some
urgeons (27–30).
Septal myectomy is performed through an aortotomy. A
ectangular trough is created by first making two parallel
ongitudinal incisions in the basal septum. Incisions are
xtended distally and then transversely connected proxi-
ally below the aortic valve and distally just beyond the
evel of mitral-septal contact and subaortic obstruction (with
tandard Morrow myectomy) or to mid-ventricular level at
he base of papillary muscles (with extended myectomy),
ielding 3 to 12 grams of septal muscle. It has been prudent
ractice to perform myectomy under intraoperative trans-
sophageal echocardiographic guidance to directly monitor
he efficacy of the resection (to identify the level of obstruc-
ion and distribution of septal hypertrophy) and allow for
ossible surgical revision.
Mitral valve repair, in addition to myectomy, may be
ost appropriate for selected patients with severe mitral
egurgitation caused by primary valvular disease (e.g., myx-
matous or rheumatic or ruptured chordae) (31–34). Occa-
ionally, if intrinsic mitral valve disease is of sufficient
everity to preclude repair, or the proximal septum is only
ildly thickened and the risks for either septal perforation
by excessive muscular resection) or residual post-operative
bstruction (by inadequate resection) are increased, then
eplacement with a low-profile mitral prosthesis without
yectomy may be prudent (31,35,36). Mitral valve replace-
ent is, however, not routinely recommended as a primary
reatment for obstruction, because of the potential post-
perative complications related to durability, thromboem-
olism, and anticoagulation (1,2,37).
Occasionally, greatly elongated and flexible mitral leaflets
ill contribute substantially to the generation of mitral-
eptal contact (38,39). In such selected cases, mitral valve
lication combined with myectomy has been performed to
estrict mitral valve motion and allow for more complete
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
LV  left ventricularelief of subaortic obstruction and mitral regurgitation 32,33,39–42). Septal myectomy also offers an opportunity
o repair associated major cardiac lesions such as atheroscle-
otic obstructive coronary artery disease or forms of fixed
ortic stenosis, or surgically treat atrial fibrillation with the
AZE procedure (43,44).
RADITIONAL ROLE FOR SEPTAL MYECTOMY
imiting exertional dyspnea (often with anginal or atypical
hest pain), fatigue, and occasionally orthopnea, paroxysmal
octurnal dyspnea, or syncope can frequently be controlled
argely by conventional drug treatment with negative ino-
ropic agents such as beta-blockers, verapamil, and disopyr-
mide (1,2,7,9–11) (Fig. 1). However, septal myectomy is
he preferred treatment intervention should such heart
ailure symptoms become refractory to maximal medical
anagement with substantial lifestyle limitation equivalent
o New York Heart Association functional classes III or IV,
n the presence of LV outflow tract obstruction (gradient
50 mm Hg under resting [basal] conditions or when
hysiologically provoked with exercise) (1,2) (Fig. 1). Chil-
ren with obstruction may be regarded as surgical candi-
ates when experiencing somewhat lesser degrees of limi-
ation.
Intervention with septal myectomy (or alcohol ablation)
ased primarily on other disease features such as atrial
brillation or unexplained syncope, in patients with the
onobstructive form of HCM, or in asymptomatic (or
ildly symptomatic) patients with outflow obstruction, is
ot recommended. Of particular note, these guidelines
overning the selection of HCM patients for myectomy
epresent the contemporary recommendations of the 2003
merican College of Cardiology-European Society of Car-
iology Expert Consensus Panel on the Management of
CM (1). Furthermore, it should be emphasized that the
tated guidelines governing selection of patients for surgical
eptal myectomy are identical to those for alcohol septal
blation (1).
URGICAL RISKS
he evolution of septal myectomy, aided by improved
yocardial preservation techniques and post-operative care,
s well as intraoperative echocardiography, has produced
ubstantial reduction in operative mortality. In the 1980s,
easonably high operative mortality rates of 5% were
eported from some centers, disproportionately reflecting
he initial surgical experience of up to 40 years ago
23,24,45–49). However, over the last 10 to 15 years,
yectomy has been performed with low mortality rates of
% to 2% or even less (although somewhat higher with
ssociated coronary artery bypass grafting or valve replace-
ent) (46,49–52). Of particular note, the major centers
erforming septal myectomy report virtually no operative
eaths in the most recent consecutive cases (including
hildren) spanning the last decade (e.g., involving up to
250 cases per institution) (1,52–57). It is most appropriate
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The Case for HCM Surgery November 16, 2004:2044–53o cite these very low contemporary mortality rates to
urrent candidates for myectomy, rather than to characterize
he risks of surgery with older and obsolete data. Such
urgical considerations are predicated on the strong prefer-
nce that septal myectomy be performed at centers (and by
urgeons) having considerable experience with obstruc-
ive HCM, and in which patient outcomes have been
nalyzed.
OST-SURGICAL RESULTS
eart failure symptoms. Based on the experience and data
ssembled from more than 25 centers worldwide over
lmost 45 years (1,2,9,10,27–33,35,39–42,45–73), septal
yectomy is established as a proven approach for reversing
he consequences of heart failure by providing permanent
melioration of obstruction (and relief of mitral regurgita-
ion) at rest, and restoring functional capacity and an
cceptable quality of life at any age, exceeding that achiev-
ble with chronic administration of cardioactive drugs (1).
hese salutary benefits are demonstrable subjectively by
atient history and objectively by increased treadmill time,
aximum workload, peak oxygen consumption, and im-
roved myocardial oxygen demand, metabolism, and coro-
ary flow (66–69).
Gradient reduction results from basal septal thinning
ith resultant widening of the LV outflow tract area (and
e-direction of forward flow with loss of the drag and
enturi effects on mitral valve) (15–17), and consequently
bolition of systolic anterior motion of the mitral valve and
igure 1. Presentation and treatment strategies for patient subgroups with
trial fibrillation; DDD  dual-chamber; ICD  implantable cardioverte
ulmonary vein; SD  sudden death; w/o  without. *No specific treatm
rom Maron et al. (1) and reproduced with permission of the American Citral-septal contact (16,18,65,70,71,73). Mitral regurgita- sion is usually virtually eliminated without the need for
dditional mitral valve surgery (72), left atrial size (and
ossibly the long-term risk for atrial fibrillation) are reduced
7,11,28,74), and LV systolic and end-diastolic pressures as
ell as wall stress are normalized (1,2,7,11,15,72,73,75).
ong-term survival. Whether relief of outflow obstruction
y septal myectomy also extends the longevity of patients
ith HCM has been an important but largely unresolved
ssue, owing to the impracticality and ethical considerations
nvolved in designing a controlled trial comparing patients
andomized to surgery and other treatments. Nevertheless,
revious reports (46,49,52–55,59–61,64) and a recently
vailable retrospective and controlled analysis of the Mayo
linic surgical series (75) provide evidence that myectomy
esults in excellent long-term survival, may alter the natural
istory of the disease, and consequently obstructive HCM
ould be regarded as a surgically correctable form of heart
ailure in many severely symptomatic patients. After septal
yectomy, long-term actuarial survival was 99%, 98%, and
5%, at 1, 5, and 10 years, respectively (when considering
CM-related mortality). Survival of myectomy patients did
ot differ from that expected in a matched general U.S.
opulation and, in fact, was superior to that achieved by
on-operated obstructed patients (75). Myectomy was also
ssociated with reduced long-term risk for sudden cardiac
eath (75), suggesting that the long-term consequences of
urgical myectomy and ablation may well be paradoxical in
his regard—that is, myectomy can decrease sudden death
isk, whereas ablation may increase that risk (at least in some
atients) (1). However, relevant long-term data for alcohol
broad clinical spectrum of hypertrophic cardiomyopathy (HCM). AF 
brillator; MAZE  surgical procedure to abolish atrial fibrillation; PV 
intervention indicated, except under exceptional circumstances. Adapted
e of Cardiology.in the
r-defieptal ablation will not be available for decades.
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November 16, 2004:2044–53 The Case for HCM SurgeryLTERNATIVES TO SURGERY
he impetus to developing alternative strategies for reliev-
ng LV outflow obstruction in severely symptomatic HCM
atients is based on the awareness that not all patients
eserving of surgery can be regarded as satisfactory candi-
ates (1,2) (Fig. 1). For example, there may be important
eographic issues (and resistance to travel) for some patients
ithout ready access to a specialized center within the U.S.
nd particularly in countries without an experienced surgical
ption, as well as medical conditions constituting obstacles
o low-risk surgery—for instance, co-morbidity or particu-
arly advanced age, or insufficient patient motivation (1).
acing. In the early 1990s, dual-chamber pacing was of-
ered as an alternative to surgery to reduce outflow obstruc-
ion and heart failure symptoms (76–79). Observational
tudies attributed considerable benefit to pacing, but subse-
uent data from randomized trials demonstrated gradient
eduction to be modest and inconsistent, and the perceived
unctional improvement largely explained as a placebo effect
69,77–79). Although a small subset of mostly older patients
ay benefit from implantation of a dual-chamber pace-
aker, this treatment has fallen from favor as a primary
lternative to myectomy in obstructive HCM and has
volved to only a limited role (1).
lcohol septal ablation. A nonsurgical, catheter-based
echnique (known by a number of acronyms) has recently
merged as an additional interventional therapy for obstruc-
ive HCM—in the process generating considerable visibility
t the expense of the older surgical option (80–90). Alcohol
eptal ablation is a percutaneous approach in which 1 to 3
l of 96% to 98% alcohol is introduced into a major septal
erforator artery to create necrosis and permanent myocar-
ial infarction in the proximal septum (80–90). Subsequent
ntramyocardial septal scarring (91) leads to progressive LV
hinning, restricted septal excursion, outflow tract enlarge-
ent, and consequent reduction in obstruction and mitral
egurgitation, thereby mimicking the remodeling that re-
ults from myectomy. Therefore, alcohol ablation is a
nique therapeutic strategy, in which hemodynamic and
linical benefit is promoted by virtue of intentionally creat-
ng myocardial damage.
HE CHALLENGE OF ALCOHOL
EPTAL ABLATION TO SURGERY
e are concerned that the unbridled enthusiasm in inter-
entional practice for alcohol septal ablation (88,90–94) has
ecome excessive without proper technical regulation and
raining requirements. This circumstance has also appar-
ntly obscured the appropriate selection of patients for
ajor intervention, and has far too often made this new
ercutaneous strategy the initial treatment for symptomatic
atients with obstructive HCM, and in the process distorted
he management strategies for patients within this hetero-
eneous disease spectrum. Unfortunately, in increasing tumbers, the surgical option is being relegated to those
atients referred directly to surgeons or with failed ablations
a clinical scenario in which surgical myectomy is more
ifficult) (95), or portrayed in a negative light with the
otential risks exaggerated while those attributable to abla-
ion are minimized (96). Remarkably, a recent editorial (96)
isrepresented management strategies in HCM by com-
letely excluding surgery from the overall HCM treatment
lgorithm, thereby arbitrarily declaring myectomy to be
utdated and obsolete. These developments could unneces-
arily undermine future patient access to what should be
onsidered the preferred treatment for symptomatic ob-
tructive HCM (i.e., septal myectomy).
Of note, even though the acknowledged hemodynamic
nd symptomatic criteria for the selection of patients un-
ergoing either myectomy or ablation are the same (1), the
ast number of alcohol ablations performed over the last
our to six years (estimated 3,500 worldwide) has reached
pidemic proportions, far exceeding—by 10- to 35-fold—
he number of surgical myectomies during the same time
eriod and also the total number of operations performed
orldwide over 45 years (88). Paradoxically, HCM surgery
n Germany is now in danger of extinction because of the
uphoria for alcohol ablation, despite the fact that myec-
omy was pioneered in Europe 40 years ago by German
urgeons (45); however, this is not the case in many other
uropean countries (such as France and Sweden) where
lcohol ablations have been performed in only limited
umbers.
To account for the excess number of alcohol septal
blations performed over a short period of time, it is
ndeniable that the threshold for limiting symptoms and
utflow gradient has been lowered well below that generally
ecommended for myectomy (1,92–94). Furthermore, it has
een the practice at some centers to target patients for
lcohol septal ablation by provoking outflow obstruction
ith non-physiologic methods, for example, administration
f dobutamine, a powerful inotropic drug known to induce
ubaortic gradients even in normal hearts (84,87,88,97–99),
nd the use of which has been strongly discouraged (1).
hese less strict patient selection criteria for alcohol ablation
ontrast sharply with the contemporary international guide-
ines of the 2003 American College of Cardiology-
uropean Society of Cardiology consensus panel (1).
Obstacles to surgical myectomy derive from certain
merging patterns, such as the difficulties perceived by many
ardiologists acting as “gate-keepers” for referring patients
ith obstructive HCM to surgery (particularly if alternative
enters are required) (73). Certainly, economic pressures in
he cardiology marketplace may understandably skew treat-
ent choices toward catheter-based interventions, which
an be performed promptly in the laboratory. Surgical septal
yectomy has been traditionally performed in tertiary
eferral centers with subspecialists who are knowledgeable
bout the HCM disease process. Similarly, it is preferred
hat alcohol ablation be undertaken in centers having a
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The Case for HCM Surgery November 16, 2004:2044–53omprehensive understanding of HCM and surgical myec-
omy, rather than preferentially in interventional practices
ocused solely on ablation, to allow for prudent management
ecisions in an environment not unduly biased toward either
herapeutic option. Certainly, the perceived relative simplic-
ty of alcohol ablation has resulted in less experienced
ractices performing this technique without the advantage
f formal training, or an expansive cardiac assessment which
s necessary for a heterogeneous and complex disease such as
CM.
HE CASE FOR SURGERY: THE “GOLD STANDARD”
lthough surgery and alcohol septal ablation both reduce
V outflow obstruction and symptoms, these two interven-
ional options cannot be regarded as entirely equivalent
rocedures. For example, two single-institution comparison
tudies report certain end points (gradient reduction and
eak oxygen consumption with exercise) to be superior with
yectomy (66,85). Indeed, with a well-performed myec-
omy, patients can expect a preoperative gradient of any
agnitude at rest to be invariably reduced to 0 to 10 mm Hg
nd not recur over time (1), and to be much less variable
han reported short-term after alcohol ablation. Because
vailable follow-up information is considerable for surgery
ver an eight-fold greater period of time (i.e., 45 years) than
or ablation (about 5 years with average cohort follow-up
2 years) (88), it remains unresolved as to whether
blation-related benefits will prove to be sustainable and
ruly long-lasting as with surgery. Also, immediate relief of
arked outflow obstruction, which may be necessary in
ome particularly symptomatic patients, can only be
chieved with surgical intervention, because alcohol ablation
equires gradual and unpredictable remodeling with pro-
ressive scarring for up to one year in order to effect
onsistent gradient reduction (1,81).
Finally, rates of permanent pacemaker implantation for
rocedure-related complete heart block are 10-fold higher
n patients undergoing ablation (5% to 25% of patients,
any who are young) (1,87,88,100,101), and some patients
re now receiving implantable defibrillators for high-risk
tatus created by the ablation itself (102). Therefore, based
n current practice and results, the most complete, perma-
ent, and pure repair for severely symptomatic patients with
bstructive HCM and heart failure can be expected with
urgical myectomy.
It should be emphasized that intramyocardial scarring of
he septum is not a consequence of septal myectomy
although localized endocardial thickening can occur) (103),
or is there evidence that surgery increases the risk for
entricular fibrillation and sudden death (1,2,73,75) or
redisposes to LV systolic dysfunction (104). However,
here are important unresolved issues surrounding the long-
erm clinical significance of the potentially arrhythmogenic
ubstrate created by alcohol-induced myocardial infarcts
either transmural or multi-focal) (91,102). Given that sany patients with HCM already harbor a pre-existing and
npredictable predisposition to ventricular tachyarrhyth-
ias (1,2,105–109), it is likely that this additional necrosis
nd scarring could only enhance the level of electrical
nstability and thereby constitute a risk factor for life-
hreatening arrhythmias and sudden death in susceptible
atients (9,107). This circumstance was documented by the
ecent report of potentially lethal arrhythmic events fre-
uently occurring shortly after ablation (102). These con-
iderations apply, in particular, to youthful patients with
ong and unpredictable periods of future risk (1,2,105–109)
n whom the “trade-off” with reduced obstruction derived
rom alcohol ablation may not convey a net benefit. How-
ver, to date, there has been little apparent reluctance to
erforming ablations in young patients. Certainly, although
onger follow-up is needed, there is sufficient reason to
resume (based on experience with atherosclerotic coronary
rtery disease) that even the relatively small infarcts pro-
uced in HCM patients by alcohol ablation could well
ncrease subsequent risk for an arrhythmic event or death
110).
Because sudden death due to ventricular arrhythmia may
ccur unexpectedly decades after diagnosis (1,2,105–109),
he relatively short follow-up available after septal ablation
t this time precludes knowledge regarding the magnitude
f that risk. Therefore, these remaining uncertainties can
nly be resolved by comprehensive post-ablation follow-up
tudies over many years. Unfortunately, however, there are
s yet virtually no systematic reports characterizing arrhyth-
ias or assessing risk stratification after ablation. Surgical
yectomy and alcohol ablation have not been subjected to a
andomized trial, but such a study design seems unlikely
iven the numerous ethical and practical obstacles, includ-
ng the substantial and largely consistent observational data
lready available for each technique, and the anticipated
bstacles to organizing such an investigation of sufficient
uration to assess late occurring cardiac events.
ELECTION OF PATIENTS FOR INTERVENTION
iven the aforementioned considerations, specialized
CM centers which offer both septal myectomy and
blation consistently express a strong preference for surgery,
specially in younger patients (55 years), but always in the
resence of severe drug-refractory heart failure symptoms
New York Heart Association functional classes III/IV)
Fig. 2). Although there are few absolute exclusions for
yectomy, alcohol ablation would be most appropriately
eserved largely for specific patient subgroups including
hose of advanced age, with significant co-mortality and
elative contraindications to surgery, or with a strong per-
onal preference for avoiding an operative procedure—in
hom proximal ventricular septal anatomy and septal per-
orator distribution and size are also judged appropriate
1,88,111) (Fig. 2). Alcohol ablation should be, however,
trongly discouraged in children or young adults, because of
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November 16, 2004:2044–53 The Case for HCM Surgeryhe potential long-term consequences of the septal scar.
therwise, the basic hemodynamic criteria for intervention
ith surgery or alcohol ablation do not differ—that is, LV
utflow tract obstruction caused by systolic anterior motion
f the mitral valve with septal contact, producing a subaortic
radient 50 mm Hg either under resting conditions or by
hysiologically based provocation with exercise (1). The LV
utflow gradients induced by the administration of dobut-
mine or other catecholamine-stimulating pharmacologic
gents are generally regarded to be of questionable physio-
ogic and clinical significance (1).
The diverse LV outflow tract morphology characteristic
f HCM may impact on proper selection of patients for
yectomy (vs. ablation) and the likelihood of a favorable
emodynamic result (1,2,29,30,38,111,112) (Fig. 2). For
xample, in a large consecutive surgical myectomy series,
lmost 20% of patients had complex and important congen-
tal, structural LV outflow tract anomalies involving the
itral apparatus, which produced or contributed to obstruc-
ion (30). These include, most prominently, the direct
nsertion of papillary muscle into the anterior mitral leaflet
associated with exaggerated anterior displacement of the
apillary muscles), producing mid-cavitary muscular ob-
truction (29,30,112). Importantly, failure to identify this
articular outflow tract anomaly will assuredly result in
ersistence of obstruction with potentially adverse proce-
ural outcome (112). Other important abnormalities in-
lude extensive fusion of hypertrophied papillary muscles to
ither ventricular septum or LV free wall, as well as fibrous
ttachments between septum and papillary muscle, LV free
all, or mitral valve which restrict mitral valve mobility and
ether the mitral apparatus toward the septum. Such mor-
hologic abnormalities are challenging to identify with
tandard echocardiographic examination (even by expert
bservers) (29,112), but are evident with intraoperative
igure 2. Each of the individual factors which favor management decisions
or respective therapeutic options in patients with obstructive hypertrophic
ardiomyopathy and drug-refractory severe symptoms (New York Heart
ssociation functional classes III/IV). LVH left ventricular hypertrophy;
AZE  surgical procedure to abolish atrial fibrillation.chocardiographic imaging (31,113,114) and to the operat- sng surgeon by direct visualization, aided by fiber-optic
eadlight and magnification with optical loupes.
In this regard, an extended septal myectomy (27–30)
although not required in many patients) allows the surgeon
o relieve muscular obstruction in the mid-cavity as well as
econstruct and widen the LV outflow tract by excising all
nomalous and accessory submitral fibrous attachments to
he septum and selectively reduce the size of hypertrophied
apillary muscles and their attachment to LV free wall. This
ffords greater flexibility and mobility to the mitral appara-
us, ensuring the most complete and sustained relief of
utflow obstruction and mitral regurgitation without pros-
hetic valve replacement. The surgeon may also tailor the
recise length and location of the myectomy trough to
ccount for mitral leaflet elongation and the potentially
ariable level of subaortic obstruction.
In contrast, creation of a myocardial infarct by alcohol is
estricted by dependency on the variable anatomic size and
he unpredictable course and perfusion distribution of the
eptal perforator arteries (86,88,111). Also, it is possible that
ome failed alcohol septal ablations (95,115,116) are attrib-
table to unrecognized anomalies of the mitral valve and
ubmitral structures. Indeed, a major distinction between
he methodology of myectomy and ablation is the greater
wareness of overall outflow tract morphology by the oper-
ting surgeon.
Part of the considerable interest in alcohol septal ablation
esides in the apparent ease with which this procedure is
erformed, in comparison to surgery, involving far less
iscomfort, shorter hospital stay, less expense, and avoid-
nce of cardiopulmonary bypass (6,80–90). Nevertheless,
he risk of procedure-related mortality due to alcohol
blation is in fact similar to (or even higher than) that
chieved in recent years at certain major centers with septal
yectomy (1,2,49,52–57,60). Furthermore, therapeutic ab-
ation failures requiring multiple procedures are common
115,116); in one recent report, almost 25% of patients
xperienced unsatisfactory clinical outcome, including those
ith the highest pre-procedural gradients (115). The need
or repeat alcohol-based interventions would not seem
esirable, particularly from the standpoint of the myocardial
car produced, and unavoidably complicates any subsequent
urgical myectomy. The true rate of nonfatal complications
nd mortality associated with alcohol ablation is, however,
nknown because such events may occur not uncommonly
n lower volume practices and be under-reported in the
iterature.
UTURE DIRECTIONS
he future management of obstructive HCM will require
xpanded patient access to surgery, to be promoted in
elected regional centers for which at least 10 myectomy
perations would be performed annually. This would, in a
roactive fashion, counteract the possible contraction of
urgical services available to patients in the future. At
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The Case for HCM Surgery November 16, 2004:2044–53resent, with the permanent closure of both the medical and
urgical HCM programs at the National Institutes of
ealth (Bethesda, Maryland), a limited number of North
merican centers remain most dedicated to the HCM
urgical option: Mayo Clinic, Cleveland Clinic, and To-
onto General Hospital, and emerging programs at St.
uke’s-Roosevelt Hospital Center (New York) and Tufts-
ew England Medical Center (Boston).
ONCLUSIONS
t this crossroads in the management of obstructive HCM,
t would seem prudent to adopt a measure of restraint before
llowing an intoxication with novel interventional technol-
gy—relatively untested over time (alcohol ablation)—to
mpair the availability of the established treatment (septal
yectomy) which has served patients with HCM exceed-
ngly well over decades and continues to merit the confi-
ence of the cardiovascular community. However, our
rguments for surgery are not intended to represent an
ndictment or rejection of the alcohol septal ablation pro-
edure. To the contrary, alcohol ablation is a promising
lternative therapy for selected patients and an important
ddition to the therapeutic armamentarium of obstructive
CM. However, its ultimate role in management is not yet
ully defined or resolved, and requires further long-term
valuation. Indeed, there is presently no justification for
romoting alcohol ablation as the standard primary thera-
eutic strategy for all severely symptomatic patients refrac-
ory to maximal medical management and with marked
bstruction to LV outflow. Septal myectomy remains the
old standard treatment option for this HCM patient
ubset.
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